Sunday’s Highlights at Noon: Teva Pharmaceutical Industries (TEVA), UnitedHealth (UNH), Ebix (EBIX), Omeros (OMER), Cormedix (CRMD)

By Carrie Williams

So far Sunday, November 17, NASDAQ is up 0.17% and the S&P is up 0.77%. Let’s take a look at this morning’s most active stocks and their recent analyst insights; Teva Pharmaceutical Industries (TEVAResearch Report), UnitedHealth (UNHResearch Report), Ebix (EBIXResearch Report), Omeros (OMERResearch Report) and Cormedix (CRMDResearch Report).

Teva Pharmaceutical Industries is up 7.71% in midday trading to $10.20. Shares opened today at $9.47. The company has a 52-week low of $6.07 and a 52-week high of $24.47. On the Street’s front, the average 12-month analyst price target for the stock is $9.80, marking a 3.48% potential upside from current levels. In a report issued on November 12, J.P. Morgan analyst Chris Schott upgraded TEVA to Hold, with a price target of $8.00, which represents a potential downside of 16% from where the stock is currently trading. Separately, on November 11, Gabelli & Co’s Kevin Kedra reiterated a Buy rating on the stock and has a price target of $20.00. Over the last 3 months, the insider sentiment on Teva Pharmaceutical Industries has been negative based on 50 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

UnitedHealth is up 5.19% in midday trading to $269.40. Shares opened today at $256.11. The company has a 52-week low of $208.07 and a 52-week high of $287.94. On the Street’s front, the average 12-month analyst price target for the stock is $279.83, marking a 9.26% potential upside from current levels. In a report issued on November 7, BMO analyst Matthew Borsch maintained a Hold rating on UNH, with a price target of $285.00, which represents a potential upside of 11% from where the stock is currently trading. Separately, on October 17, Mizuho’s Ann Hynes initiated coverage with a Buy rating on the stock and has a price target of $270.00. In the last 30 days, insiders have sold $6.78M worth of UNH shares. Over the last 3 months, the insider sentiment on UnitedHealth has been negative based on 171 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

Ebix is up 4.8% in midday trading to $34.50. Shares opened today at $32.92. The company has a 52-week low of $32.15 and a 52-week high of $63.89. On the Street’s front, the average 12-month analyst price target for the stock is $46.00, marking a 39.73% potential upside from current levels. In a report issued on November 13, BMO analyst James Fotheringham maintained a Hold rating on EBIX, with a price target of $46.00, which implies an upside of 40% from current levels. Over the last 3 months, the insider sentiment on Ebix has been negative based on 11 corporate insider transactions. This sentiment is lower than the average sector sentiment of insiders.

See today’s analyst top recommended stocks >>

Omeros is down -4.76% in midday trading to $13.20. Shares opened today at $13.86. The company has a 52-week low of $10.30 and a 52-week high of $20.92. On the Street’s front, the average 12-month analyst price target for the stock is $26.00, marking a 87.59% potential upside from current levels. In a report issued on November 15, Wedbush analyst Liana Moussatos reiterated a Hold rating on OMER, with a price target of $18.00, which represents a potential upside of 30% from where the stock is currently trading. Separately, on November 13, Maxim Group’s Jason McCarthy maintained a Buy rating on the stock and has a price target of $25.00.

Cormedix is up 4.51% in midday trading to $5.56. Shares opened today at $5.32. The company has a 52-week low of $4.86 and a 52-week high of $13.70. On the Street’s front, the average 12-month analyst price target for the stock is $14.00, marking a 163.16% potential upside from current levels. In a report issued on October 17, H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on CRMD, with a price target of $14.00, which represents a potential upside of 163% from where the stock is currently trading. Over the last 3 months, the insider sentiment on Cormedix has been positive based on 30 corporate insider transactions. This sentiment is slightly higher than the average sector sentiment of insiders.

Trending Stocks Based on Insider Activity >>